Have a conversation
For women who have plateaued on tirzepatide at 10 or 15mg, the transition to retatrutide is one of the most clinically rational next steps available
Disposition : Structure: Acylated peptide with a fatty diacid moiety extends half-life via albumin binding Half-life: ~6 days supports once-weekly dosing Administration: Subcutaneous injection Clinical Data Highlights : Weight Loss: Up to 24.2% body weight reduction in phase 2 trials, highest recorded among incretin-based therapies Glycemic Control: HbA1c reductions of 2.02.5% in type 2 diabetes patients Lipid Profile: Significant drops in triglycerides, LDL-C, and liver fat content Insulin Sensitivity: Improved HOMA-IR and fasting insulin levels Energy Expenditure: Increased basal metabolic rate and fat oxidation via glucagon receptor activation For a full breakdown of Retatrutide clinical trials and results you can click the link
Currently, the Food and Drug Administration (FDA) has approved seven GLP-1 prescription medications: When used in addition to a reduced calorie diet and increased physical activity , these medications are FDA approved for one or more of the following: Improving blood sugar levels in adults with T2D
A new study published in The researchers found that people with type 2 diabetes taking GLP-1 drugs are more likely to experience alopecia, particularly non-scarring alopecia
GLP-1 medications may offer meaningful benefits for some people living with MS by: At the same time, its important to be clear: When used thoughtfully, they may be one piece of a broader approach to health alongside MS medications, rehabilitation, nutrition, movement, mental health support, and community
/assets/images/provider/photos/2813769.png)
